Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

New York City Observational Study of Mpox Immunity

Conditions: Mpox
HIV
Monkeypox

First Posted Date: 2022-12-16

Last Posted Date: 2024-12-20

Lead Sponsor: NYU Langone Health

Target Recruit Count: 174

Registration Number: NCT05654883

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Flatbush FHC Proactive Colorectal Cancer Screening and Navigation

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Behavioral: Usual Care
Behavioral: Proactive CRC Screening Outreach

First Posted Date: 2022-12-12

Last Posted Date: 2024-12-27

Lead Sponsor: NYU Langone Health

Target Recruit Count: 109

Registration Number: NCT05646355

Locations: 🇺🇸
NYU Brooklyn Family Health Centers, Brooklyn, New York, United States

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

Phase 4

Recruiting

Conditions: Type 1 Diabetes

Interventions: Drug: Evolocumab Cartridge
Drug: Atorvastatin Calcium Tablets
Drug: Ezetimibe Tablets
Drug: 18F-FDG
Device: Angiocatheter 20IV
Device: J-Wire
Device: GlycoCheck Glycocalyx Measurement Software

First Posted Date: 2022-12-08

Last Posted Date: 2025-03-03

Lead Sponsor: NYU Langone Health

Target Recruit Count: 125

Registration Number: NCT05641753

Locations: 🇺🇸
New York VA Hospital, New York, New York, United States
🇺🇸
NYC Health + Hospitals/Bellevue, New York, New York, United States
🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

and more 1 locations

Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia
Schizophrenia Schizoaffective

Interventions: Device: PLIFUS
Device: Sham PLIFUS
Device: MRI

First Posted Date: 2022-12-08

Last Posted Date: 2025-05-30

Lead Sponsor: NYU Langone Health

Target Recruit Count: 15

Registration Number: NCT05643196

Locations: 🇺🇸
NYU Langone Brooklyn, Brooklyn, New York, United States
🇺🇸
NYU Langone Health, New York, New York, United States

UB-312 in Patients With Synucleinopathies

Phase 1

Active, not recruiting

Conditions: Parkinson Disease
Multiple System Atrophy

Interventions: Biological: UB-312 Injection
Biological: Placebo Injection

First Posted Date: 2022-12-02

Last Posted Date: 2024-07-31

Lead Sponsor: NYU Langone Health

Target Recruit Count: 8

Registration Number: NCT05634876

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Study of the Aliviado DSD Caregiving Mastery Program

Not Applicable

Completed

Conditions: Delirium Superimposed on Dementia

Interventions: Behavioral: Aliviado DSD Caregiving Mastery Program

First Posted Date: 2022-11-29

Last Posted Date: 2025-02-19

Lead Sponsor: NYU Langone Health

Target Recruit Count: 33

Registration Number: NCT05630014

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

MAGIK for Femoral/Tibial Shaft Fractures

Phase 2

Withdrawn

Conditions: Femoral Shaft Fracture
Tibial Shaft Fracture

Interventions: Drug: GIK solution
Drug: Isotonic Normal Saline Solution

First Posted Date: 2022-11-25

Last Posted Date: 2025-03-06

Lead Sponsor: NYU Langone Health

Target Recruit Count: 50

Registration Number: NCT05627479

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

Phase 2

Active, not recruiting

Conditions: Graft Vs Host Disease

Interventions: Drug: Cyclophosphamide
Drug: Abatacept
Drug: Tacrolimus

First Posted Date: 2022-11-18

Last Posted Date: 2025-04-01

Lead Sponsor: NYU Langone Health

Target Recruit Count: 27

Registration Number: NCT05621759

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA)

Phase 2

Completed

Conditions: Primary Progressive Aphasia

Interventions: Device: Transcranial Direct Current Stimulation (tDCS)
Behavioral: Word-Naming Activity

First Posted Date: 2022-11-14

Last Posted Date: 2023-12-18

Lead Sponsor: NYU Langone Health

Target Recruit Count: 10

Registration Number: NCT05615922

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

Active, not recruiting

Conditions: Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection

Interventions: Drug: PET Tracer
Drug: MRI Tracer
Device: 3T PET/MRI

First Posted Date: 2022-11-14

Last Posted Date: 2025-01-14

Lead Sponsor: NYU Langone Health

Target Recruit Count: 30

Registration Number: NCT05615415

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy